Evidence map›Paper›PMID 41068180›Full record

ReviewNPJ biofilms and microbiomes2025

Optimizing breast cancer chemotherapy by harnessing gut microbiota with insights from artificial intelligence.

Yi Zhou, Min Jiang, Ke Shen, Tao He, Siyu Zhou, Aibin Shao, Xiaoyu Li, Jiao Wang, Rongrong Wu, Rajeev K Singla and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in NPJ biofilms and microbiomes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yi ZhouDepartment of Breast Surgery and Institute for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Min JiangDepartment of Breast Surgery and Institute for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Ke ShenDepartment of Breast Surgery and Institute for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Tao HeDepartment of Breast Surgery and Institute for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Siyu ZhouDepartment of Breast Surgery and Institute for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Aibin ShaoDepartment of Breast Surgery and Institute for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Xiaoyu LiDepartment of Breast Surgery and Institute for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Jiao WangDepartment of Breast Surgery and Institute for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Rongrong WuDepartment of Breast Surgery and Institute for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Rajeev K SinglaDepartment of Breast Surgery and Institute for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Jonathan P JacobsVatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. JJacobs@mednet.ucla.edu.
Bairong ShenDepartment of Breast Surgery and Institute for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China. bairong.shen@scu.edu.cn.

Funding

National Natural Science Foundation of China 32070671
6 · The paper itself

Abstract

Optimizing chemotherapy for breast cancer (BC) remains a critical challenge. Gut microbiota (GM) dysbiosis, varying across BC subtypes and stages, influences BC development and chemotherapy response through immune and metabolic pathways. Chemotherapy also disrupts the microbiota, creating a complex bidirectional interaction. Integrating artificial intelligence (AI) allows the identification of hidden patterns, deepening our understanding of the microbiota's role. This integrated approach promises to revolutionize BC treatment with novel insights and personalized interventions.

Indexed as

Antineoplastic AgentsArtificial IntelligenceBreast NeoplasmsGastrointestinal MicrobiomeDysbiosisFemaleHumansAntineoplastic Agents

Identifiers

PMID41068180
PMCPMC12511378

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.